LAUSR

Aims: Mesenchymal stem/stromal cells (MSCs) hold promises for the treatment of diverse diseases and regeneration of injured tissues. Genetic modification of MSCs through gene delivery might enhance their therapeutic potential. Adiponectin has been appeared as a potential biomarker for predicting various diseases. Plasma adiponectin levels are negatively correlated with various metabolic and vascular diseases and supplementation of exogenous adiponectin ameliorates the diseases. This study aims to develop adiponectin secreting genetically modified MSCs (GM‐MSCs) as a potent strategic tool to complement endogenous adiponectin for the treatment of adiponectin deficiency diseases. Main methods: Human bone marrow derived MSCs were isolated, expanded in vitro and transfected with adiponectin gene containing plasmid vector. Total RNA was extracted and cDNA was prepared by reverse transcription polymerase chain reaction (RT‐PCR). The expression of adiponectin gene and protein in GM‐MSCs was analyzed by PCR and Western blotting respectively. The secretion of adiponectin protein from GM‐MSCs was analyzed by enzyme‐linked immunosorbent assay. Key findings: The expression of adiponectin gene and plasmid DNA was detected in GM‐MSCs but not in control group of MSCs. Adiponectin gene expression was detected in GM‐MSCs at 2, 7, 14, 21 and 28 days after transfection. Western blotting analysis revealed the expression of adiponectin protein only in GM‐MSCs. The GM‐MSCs stably secreted adiponectin protein into culture media at least for 4 weeks. Significance: GM‐MSCs express and secret adiponectin protein. Therefore, these adiponectin secreting GM‐MSCs could be instrumental for the supplementation of adiponectin in the treatment of adiponectin deficiency related diseases.